Down-regulation of miR-125a-3p in human gastric cancer and its clinicopathological significance

International Journal of Oncology

Volumn 40, Issue 5, 2012, Pages 1477-1482

  Hashiguchi, Yojiro ^a   Nishida, Naohiro ^b,c   Mimori, Koshi ^b   Sudo, Tomoya ^b   Tanaka, Fumiaki ^b   Shibata, Kohei ^b   Ishii, Hideshi ^b,c   Mochizuki, Hidetaka ^a   Hase, Kazuo ^a   Doki, Yuichiro ^c   Mori, Masaki ^c  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinical significance; microRNA; miR 125a 3p; Partner strand

Indexed keywords

MICRORNA; MICRORNA 125A 3P; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; TUMOR VOLUME;

AGED; CELL LINE, TUMOR; CELL PROLIFERATION; CHI-SQUARE DISTRIBUTION; DOWN-REGULATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PERITONEAL NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTORS; STOMACH NEOPLASMS; TIME FACTORS; TRANSFECTION; TUMOR BURDEN;

EID: 84860271323     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1363     Document Type: Article

References (29)

1. Boku N, Yamamoto S, Fukuda H, et al: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10: 1063-1069, 2009.
2. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W and Sobue T: Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 41: 139-147, 2011.
3. Hamaguchi T, Shirao K, Ohtsu A, et al: A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial). Gastric Cancer 14: 226-233, 2011.
4. Bang YJ, van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.
5. Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
6. Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233, 2009.
7. Nicoloso MS, Spizzo R, Shimizu M, Rossi S and Calin GA: MicroRNAs - the micro steering wheel of tumour metastases. Nat Rev Cancer 9: 293-302, 2009.
8. Spizzo R, Nicoloso MS, Croce CM and Calin GA: SnapShot: microRNAs in cancer. Cell 137: 586-586.e1, 2009.
9. Motoyama K, Inoue H, Mimori K, et al: Clinicopathological and prognostic significance of PDCD4 and microRNA-21 in human gastric cancer. Int J Oncol 36: 1089-1095, 2010.
10. Nishida N, Mimori K, Fabbri M, et al: MicroRNA-125a-5p is an independent prognostic factor in gastric cancer, and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res 17: 2725-2733, 2011.
11. Ding L, Xu Y, Zhang W, et al: MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res 20: 784-793, 2010.
12. Tsukamoto Y, Nakada C, Noguchi T, et al: MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res 70: 2339-2349, 2010.
13. Craig VJ, Cogliatti SB, Rehrauer H, Wundisch T and Muller A: Epigenetic silencing of microRNA-203 dysregulates ABL1 expression and drives Helicobacter-associated gastric lymphomagenesis. Cancer Res 71: 3616-3624, 2011.
14. Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara K and Mori M: Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res 14: 2334-2340, 2008. (Pubitemid 351551065)
15. Chiang HR, Schoenfeld LW, Ruby JG, et al: Mammalian micro-RNAs: experimental evaluation of novel and previously annotated genes. Genes Dev 24: 992-1009, 2010.
16. Yang JS, Phillips MD, Betel D, et al: Widespread regulatory activity of vertebrate microRNA*species. RNA 17: 312-326, 2011.
17. Japanese Gastric Cancer: A Japanese Classification of Gastric Carcinoma. 2nd English edition. Gastric Cancer 1: 10-24, 1998.
18. Mori M, Mimori K, Yoshikawa Y, et al: Analysis of the gene-expression profile regarding the progression of human gastric carcinoma. Surgery 131 (Suppl): 39-47, 2002.
19. Jiang L, Huang Q, Zhang S, et al: Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. BMC Cancer 10: 318, 2010.
20. Hisaoka M, Matsuyama A, Nagao Y, et al: Identification of altered microRNA expression patterns in synovial sarcoma. Genes Chromosomes Cancer 50: 137-145, 2011.
21. Xu X, Jia R, Zhou Y, et al: Microarray-based analysis: identification of hypoxia-regulated microRNAs in retinoblastoma cells. Int J Oncol 38: 1385-1393, 2011.
22. Guo X, Wu Y and Hartley RS: MicroRNA-125a represses cell growth by targeting HuR in breast cancer. RNA Biol 6: 575-583, 2009.
23. Li W, Duan R, Kooy F, Sherman SL, Zhou W and Jin P: Germline mutation of microRNA-125a is associated with breast cancer. J Med Genet 46: 358-360, 2009.
24. O'Day E and Lal A: MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 12: 201, 2010.
25. Nam EJ, Yoon H, Kim SW, et al: MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 14: 2690-2695, 2008.
26. Wang G, Mao W, Zheng S and Ye J: Epidermal growth factor receptor-regulated miR-125a-5p - a metastatic inhibitor of lung cancer. FEBS J 276: 5571-5578, 2009.
27. Ferretti E, De Smaele E, Po A, et al: MicroRNA profiling in human medulloblastoma. Int J Cancer 124: 568-577, 2009.
28. Garzon R, Marcucci G and Croce CM: Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 9: 775-789, 2010.
29. Kota J, Chivukula RR, O'Donnell KA, et al: Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137: 1005-1017, 2009.